PHARM SRL has established contracts with Pharmaceutical Companies and Research Institutions.
Acted as a subcontractor in a Seventh Framework Programme (FP7) funded project (DEferiprone Evaluation in Pediatrics – DEEP, for the evaluation of a paediatric formulation of deferiprone) for regulatory and ethics submissions in several EU and non EU countries concerning a wide safety-efficacy paediatric clinical trial which was successfully completed in 2017.
PHARM SRL has obtained in 2015 the approval for a Paediatric Investigation Plan (PIP) for the clinical research and commercial development of the off-label drug gabapentin for the treatment of neuropathic chronic pain.
This approval allowed the constitution of a large international consortium funded under the FP7 framework involving Public Research Institutions, a Pharmaceutical Company, a Patient Association and two two Small and Medium-sized Enterprises (SMEs), and in which PHARM plays a pivotal role as Sponsor (see GAPP project).
These experiences acted as a springboard for launching PHARM in a more active role in paediatric research, in line with the primary company’s remit.